Formycon AG
http://www.formycon.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Formycon AG
Formycon Reports Positive Phase III Data On Ustekinumab
Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.
Cimerli Interchangeable Biosimilar Approved Without Switching Data
Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.
Interchangeable Biosimilar Approved Without Switching Data; Cimerli To Compete With Lucentis
Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.
Who’s Hired? Former Hikma Chief Olafsson Takes Lead At Mallinckrodt
Siggi Olafsson has taken the reins at Mallinckrodt after stepping down as Hikma’s CEO. At the same time, Teva has named a new global R&D and chief medical officer while Piramal Pharma Solutions has appointed a fresh COO and Formycon has added to its supervisory board.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule